The effect of Selenium supplementation in high risk mothers for Preeclampsia screened with Quadruple tests

The effect of Selenium supplementation on clinical outcomes of Preeclampsia, metabolic profiles, and Pulsatility Index (PI ) of uterine artery in Doppler sonography in high risk mothers screening with Quadruple tests

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200608047701N1

Enrollment

Registered

2020-06-26

Start date

2020-07-20

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre-eclampsia. Pre-eclampsia

Interventions

Intervention 1: Intervention group:200 micrograms of selenium capsules (Alpha Vitamins , Arian Sena , Tehran , Iran),1 daily, orally for 12 weeks . Intervention duration: 12 weeks . Intervention 2: Co

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: High-risk pregnant women for pre-eclampsia screened with Quadruple tests Age of 18 to 40 Pregnant woman living in Kashan First pregnancy Single pregnancy Lack of bone and chromosomal abnormalities Complete the consent form

Exclusion criteria

Exclusion criteria: Lack of willingness to cooperate at any stage of the project Under age of 18 years old Pregnant women who are currently smoking (Low risk for preeclampsia ) Pregnant women who are taking selenium supplements Pregnant women who are taking thyroid medication Pregnant women who are taking Aspirin , Heparin or Anti hypertensive drugs Pregnant women who have chronic proteinuria Abnormal scan anomalies

Design outcomes

Primary

Measure	Time frame
Highly sensitive C-reactive protein (Hs-CRP). Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Eliza Kit.	—

Secondary

Measure	Time frame
Systolic and diastolic blood pressure levels. Timepoint: At the beginning of the study and then twice a week. Method of measurement: Mercury sphygmomanometer.;Nitric Oxide. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Total antioxidants. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Malone De Aldeid. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Pulsatility Index of Uterine artery. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Caller Doppler ultrasound.;Serum hemoglobin. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: laboratory kit.;Serum Platelet. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: laboratory kit.;Liver transaminases. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: laboratory kit.;Serum Creatinine. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: laboratory kit.;Serum Uric acid. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: laboratory kit.;Body Mass Index ( BMI ). Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Weight by scales , Height by meter.;Urinary protein excretion. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Urine sample.	—

Measure

Time frame

Systolic and diastolic blood pressure levels. Timepoint: At the beginning of the study and then twice a week. Method of measurement: Mercury sphygmomanometer.;Nitric Oxide. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Total antioxidants. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Malone De Aldeid. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Pulsatility Index of Uterine artery. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Caller Doppler ultrasound.;Serum hemoglobin. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: laboratory kit.;Serum Platelet. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: laboratory kit.;Liver transaminases. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: laboratory kit.;Serum Creatinine. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: laboratory kit.;Serum Uric acid. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: laboratory kit.;Body Mass Index ( BMI ). Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Weight by scales , Height by meter.;Urinary protein excretion. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Urine sample.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarah Shahin

Kashan University of Medical Sciences

farahshahin660@yahoo.com+98 31 5554 0021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 19, 2026